Hijacking the chromatin remodeling machinery: Impact of SWI/SNF perturbations in cancer

Cancer Research

Volumn 69, Issue 21, 2009, Pages 8223-8230

  Weissman, Bernard ^a   Knudsen, Karen E ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; PROTEIN SUBUNIT; PROTEIN SWI; TRANSCRIPTION FACTOR SNF;

CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENZYME MECHANISM; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TREATMENT RESPONSE;

ANIMALS; CHROMATIN; CHROMOSOMAL PROTEINS, NON-HISTONE; HUMANS; NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 70350539592     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2166     Document Type: Review

References (96)

1. Wu JI, Lessard J, Crabtree GR. Understanding the words of chromatin regulation. Cell 2009;136:200-206
2. Trotter KW, Archer TK. Nuclear receptors and chromatin remodeling machinery. Mol Cell Endocrinol 2007;265-6:162-167
3. Halliday GM, Bock VL, Moloney FJ, Lyons JG. SWI/SNF: a chromatin-remodelling complex with a role in carcinogenesis. Int J Biochem Cell Biol 2009;41:725-728
4. Reisman D, Glaros S, T hompson EA. The SWI/SNF complex and cancer. Oncogene 2009;28:1653-1668
5. Keppler BR, Archer TK. Chromatin-modifying enzymes as therapeutic targets-Part 1. Expert Opin Ther Targets 2008;12:1301-1312
6. Keppler BR, Archer TK. Chromatin-modifying enzymes as therapeutic targets-Part 2. Expert Opin Ther Targets 2008;12:1457-1467
7. Lessard J, Wu JI, Ranish JA, et al. An essential switch in subunit composition of a chromatin remodeling complex during neural development. Neuron 2007;55: 201-215 (Pubitemid 47048906)
8. Wang W, Cote J, Xue Y, et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 1996;15:5370-5382 (Pubitemid 26336219)
9. Phelan ML, Sif S, Narlikar GJ, Kingston RE. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell 1999;3:247-253 (Pubitemid 29292625)
10. Chen J, Archer TK. Regulating SWI/SNF subunit levels via protein-protein interactions and proteasomal degradation: BAF155 and BAF170 limit expression of BAF57. Mol Cell Biol 2005;25:9016-9027 (Pubitemid 41429090)
11. Stojanova A, Penn LZ. The role of INI1/hSNF5 in gene regulation and cancer. Biochem Cell Biol 2009;87: 163-177
12. Sansam CG, Roberts CW. Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle 2006;5:621-624
13. Ho L, Jothi R, Ronan JL, Cui K, Zhao K, Crabtree GR. An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network. Proc Natl Acad Sci U S A 2009;106:5187-5191
14. Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE. Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol 2001;186:136-145
15. Fukuoka J, Fujii T, Shih JH, et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 2004;10:4314-4324 (Pubitemid 38878869)
16. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene 2007;26:7058-7066 (Pubitemid 350014614)
17. Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M. Genetic and epigenetic screening for gene alterations of the chromatinremodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes Cancer 2004;41:170-177 (Pubitemid 39096743)
18. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003;63:560-566 (Pubitemid 36158131)
19. Reisman DN, Strobeck MW, Betz BL, et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 2002;21: 1196-1207
20. Wong AK, Shanahan F, Chen Y, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 2000;60:6171-6177 (Pubitemid 30839650)
21. Teare MD, Rohde K, Santibanez Koref MF. The use of loss of constitutional heterozygosity data to ascertain the location of predisposing genes in cancer families. J Med Genet 1994;31:448-452 (Pubitemid 24182936)
22. Hoglund M, Gorunova L, Andren-Sandberg A, Dawiskiba S, Mitelman F, Johansson B. Cytogenetic and fluorescence in situ hybridization analyses of chromosome 19 aberrations in pancreatic carcinomas: frequent loss of 19p13.3 and gain of 19q13.1-13.2. Genes Chromosomes Cancer 1998;21:8-16. (Pubitemid 28028103)
23. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer 2000;27:244-251
24. Oesterreich S, Allredl DC, Mohsin SK, et al. High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer 2001;84:493-498 (Pubitemid 32215876)
25. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001;61:1309-1313 (Pubitemid 34292548)
26. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999;154:1835-1840
27. Wang ZJ, Churchman M, Campbell IG, et al. Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer 1999;80:70-72 (Pubitemid 29210090)
28. Westerman AM, Entius MM, Boor PP, et al. Novel mutations in the LKB1/STK11 gene in Dutch Peutz- Jeghers families. Hum Mutat 1999;13:476-481 (Pubitemid 29270018)
29. Jiang CY, Esufali S, Berk T, et al. STK11/LKB1 germline mutations are not identified in most Peutz-Jeghers syndrome patients. Clin Genet 1999;56:136-141 (Pubitemid 29433595)
30. Chen J, Lindblom A. Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p. Clin Genet 2000;57:394-397 (Pubitemid 30245827)
31. Astbury C, Jackson-Cook CK, Culp SH, Paisley TE, Ware JL. Suppression of tumorigenicity in the human prostate cancer cell line M12 via microcell-mediated restoration of chromosome 19. Genes Chromosomes Cancer 2001;31:143-155 (Pubitemid 32411040)
32. Gao AC, Lou W, Ichikawa T, Denmeade SR, Barrett JC, Isaacs JT. Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. Prostate 1999;38:46-54. (Pubitemid 29011017)
33. Bultman S, Gebuhr T, Yee D, et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell 2000;6:1287-1295 (Pubitemid 32045922)
34. Bultman SJ, Herschkowitz JI, Godfrey V, et al. Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 2008;27:460-468
35. Glaros S, Cirrincione GM, Palanca A, Metzger D, Reisman D. Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res 2008;68:3689-3696
36. Medina PP, Romero OA, Kohno T, et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 2008;29:617-622 (Pubitemid 351614585)
37. Reyes JC, Barra J, Muchardt C, Camus A, Babinet C, Yaniv M. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2á). EMBO J 1998; 17:6979-6991 (Pubitemid 28550292)
38. Sun A, Tawfik O, Gayed B, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 2007;67:203-213 (Pubitemid 46185323)
39. Shen H, Powers N, Saini N, et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res 2008;68:10154-10162
40. Yamamichi N, Inada K, Ichinose M, et al. Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res 2007;67:10727-10735 (Pubitemid 350145899)
41. Yamamichi N, Yamamichi-Nishina M, Mizutani T, et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene 2005;24:5471-5481 (Pubitemid 43080090)
42. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203-206 (Pubitemid 28325977)
43. DeCristofaro MF, Betz BL, Wang W, Weissman BE. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. Oncogene 1999;18:7559-7565 (Pubitemid 30035057)
44. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-79 (Pubitemid 29062960)
45. Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002;8:3461-3467 (Pubitemid 35340722)
46. Biegel JA, Fogelgren B, Zhou JY, et al. Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system. Clin Cancer Res 2000;6: 2759-2763 (Pubitemid 30482115)
47. Biegel JA, Fogelgren B, Wainwright LM, Zhou JY, Bevan H, Rorke LB. Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor. Genes Chromosomes Cancer 2000;28:31-37 (Pubitemid 30176760)
48. Sévenet N, Lellouch-Tubiana A, Schofield D, et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 1999;8:2359-2368
49. Sévenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 1999;65:1342-1348 (Pubitemid 30460384)
50. Savla J, Chen TT, Schneider NR, Timmons CF, Delattre O, Tomlinson GE. Mutations of the hSNF5/ INI1 gene in renal rhabdoid tumors with second primary brain tumors. J Natl Cancer Inst 2000;92:648-650 (Pubitemid 30321308)
51. Janson K, Nedzi LA, David O, et al. Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer 2005;47:279-284
52. Hoot AC, Russo P, Judkins AR, Perlman EJ, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol 2004;28:1485-1491 (Pubitemid 39425515)
53. Biegel JA. Molecular genetics of atypical teratoid/ rhabdoid tumor. Neurosurg Focus 2006;20:E11.
54. Modena P, Lualdi E, Facchinetti F, et al. SMARCB1/ INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 2005;65:4012-4019 (Pubitemid 40775637)
55. Ammerlaan AC, Ararou A, Houben MP, et al. Longterm survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. Br J Cancer 2008;98:474-479 (Pubitemid 351161248)
56. Hulsebos TJ, Plomp AS, Wolterman RA, Robanus- Maandag EC, Baas F, Wesseling P. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 2007;80:805-810 (Pubitemid 46564417)
57. Bourdeaut F, Freneaux P, Thuille B, et al. hSNF5/ INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol 2007; 211:323-330 (Pubitemid 46172708)
58. Gessi M, Giangaspero F, Pietsch T. Atypical teratoid/ rhabdoid tumors and choroid plexus tumors: when genetics "surprise" pathology. Brain Pathol 2003;13: 409-414
59. Guidi CJ, Sands AT, Zambrowicz BP, et al. Disruption of ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 2001;21:3598-3603
60. Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C, Yaniv M. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 2000;1:500-506
61. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH. Haploinsufficiency of snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci U S A 2000;97: 13796-13800
62. Roberts CW, Leroux MM, Fleming MD, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2002;2:415-425
63. Sohn DH, Lee KY, Lee C, et al. SRG3 interacts directly with the major components of the SWI/SNF chromatin remodeling complex and protects them from proteasomal degradation. J Biol Chem 2007;282:10614-10624 (Pubitemid 47093407)
64. Maitra A, Wistuba II, Washington C, et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 2001;159:119-130 (Pubitemid 33704198)
65. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60:1949-1960 (Pubitemid 30207657)
66. Heeboll S, Borre M, Ottosen PD, et al. SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol 2008;23:1069-1076
67. Andersen CL, Christensen LL, Thorsen K, et al. Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer 2009;100:511-523
68. Shadeo A, Chari R, Lonergan KM, et al. Up regulation in gene expression of chromatin remodelling factors in cervical intraepithelial neoplasia. BMC Genomics 2008;9:64.
69. Ralhan R, Desouza LV, Matta A, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008; 7:1162-1173 (Pubitemid 351943962)
70. Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer 2007;46: 745-750 (Pubitemid 46912345)
71. Nagl NG, Jr., Wang X, Patsialou A, Van Scoy M, Moran E. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J 2007;26:752-763 (Pubitemid 46253849)
72. Xia W, Nagase S, Montia AG, et al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res 2008;68: 1667-1674
73. Oh J, Sohn DH, Ko M, Chung H, Jeon SH, Seong RH. BAF60a interacts with p53 to recruit the SWI/SNF complex. J Biol Chem 2008;283:11924-11934
74. Takita J, Ishii M, Tsutsumi S, et al. Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer 2004;40:120-132 (Pubitemid 38579880)
75. Hoyal CR, Kammerer S, Roth RB, et al. Genetic polymorphisms in DPF3 associated with risk of breast cancer and lymph node metastases. J Carcinog 2005;4:13. (Pubitemid 41461122)
76. Wang M, Gu C, Qi T, et al. BAF53 interacts with p53 and functions in p53-mediated p21-gene transcription. J Biochem 2007;142:613-620 (Pubitemid 351197696)
77. Lee K, Shim JH, Kang MJ, et al. Association of BAF53 with mitotic chromosomes. Mol Cells 2007;24:288-293
78. Belandia B, Orford RL, Hurst HC, Parker MG. Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J 2002;21: 4094-4103 (Pubitemid 34857441)
79. Kiskinis E, Garcia-Pedrero JM, Villaronga MA, Parker MG, Belandia B. Identification of BAF57 mutations in human breast cancer cell lines. Breast Cancer Res Treat 2006;98:191-198 (Pubitemid 44050769)
80. Link KA, Burd CJ, Williams E, et al. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Mol Cell Biol 2005; 25:2200-2215 (Pubitemid 40354619)
81. Link KA, Balasubramaniam S, Sharma A, et al. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res 2008;68:4551-4558
82. Sumi-Ichinose C, Ichinose H, Metzger D, Chambon P. SNF2β-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells. Mol Cell Biol 1997;17: 5976-5986 (Pubitemid 27411105)
83. Bourgo RJ, Siddiqui H, Fox S, et al. SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Mol Cell Biol 2009;20:3192-3199
84. Pottier N, Yang W, Assem M, et al. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst 2008;100:1792-1803
85. Holleman A, Cheok MH, den Boer ML, et al. Geneexpression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-542 (Pubitemid 39025170)
86. Pottier N, Cheok MH, Yang W, et al. Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Hum Mol Genet 2007;16:2261-2271 (Pubitemid 47423892)
87. Zhang B, Chambers KJ, Faller DV, Wang S. Reprogramming of the SWI/SNF complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation. Oncogene 2007;26:7153-7157 (Pubitemid 350059673)
88. Asp P, Wihlborg M, Karlen M, Farrants AK. Expression of BRG1, a human SWI/SNF component, affects the organisation of actin filaments through the RhoA signalling pathway. J Cell Sci 2002;115:2735-2746 (Pubitemid 34846514)
89. Banine F, Bartlett C, Gunawardena R, et al. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res 2005;65:3542-3547 (Pubitemid 40616328)
90. Strobeck MW, DeCristofaro MF, Banine F, Weissman BE, Sherman LS, Knudsen ES. The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J Biol Chem 2001;276:9273-9278 (Pubitemid 37385511)
91. Cheng JX, Tretiakova M, Gong C, Mandal S, Krausz T, Taxy JB. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol 2008;21:647-652 (Pubitemid 351744839)
92. Roberts CW, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 2009; 8:412-416
93. Luo B, Cheung HW, Subramanian A, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A 2008;105:20380-20385
94. Aoyagi S, Trotter KW, Archer TK. ATP-dependent chromatin remodeling complexes and their role in nuclear receptor-dependent transcription in vivo. Vitam Horm 2005;70:281-307.
95. Dai Y, Ngo D, Jacob J, Forman LW, Faller DV. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis 2008;29:1725-1733
96. Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 2006;5:2324-2328 (Pubitemid 44801377)